Verona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth Prospects
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...
Verona Pharma price target raised to $42 from $36 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 ...
Verona Pharma plc (NASDAQ:VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market.
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...
kalkinemedia1d
Verona Pharma (NASDAQ:VRNA) Reports Q3 2024 Results with Promising Ohtuvayre™ Launch
Highlights:,Ohtuvayre™ generates $5.6 million in net sales in its first seven weeks, signaling a strong market entry.,October ...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...
bovnews2d
The Stock Market’s Hidden Gem: Why Verona Pharma (VRNA) Is On the Rise
At the heart of Verona Pharma’s recent success is Ohtuvayre (ensifentrine), a revolutionary treatment for chronic obstructive pulmonary disease (COPD). According to David Zaccardelli, the President ...
Verona Pharma Q3 2024 Earnings Preview
Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.